New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
16:31 EDTTRV, ARNA, RIMM, BOX, MSFT, DELL, VZ, DD, JNJ, IIVIOn The Fly: Closing Wrap
Stocks on Wall Street were slightly higher after four Dow components reported mixed quarterly results before the bell. The earnings calendar is fairly heavy again after the bell, as investors receive results from tech giants Google (GOOG) and International Business Machines (IBM) among those reporting... ECONOMIC EVENTS: In the U.S., sales of existing homes unexpectedly dropped 1% in December to a 4.94M annual rate, versus expectations for sales to increase to a 5.1M rate. Two regional Fed surveys were also reported, with the Chicago Fed National Activity Index slipping but remaining positive at 0.02, while the Richmond Fed Manufacturing Survey plunged 17 points to -12... COMPANY NEWS: Among the four Dow members reporting results, Travelers (TRV) was the leader, gaining $1.64, or 2.15%, to $77.95 after its better than expected earnings. Shares of DuPont (DD) and Verizon (VZ) were also higher. Johnson & Johnson (JNJ) slid 54c, or 0.74%, to $72.69 after its quarterly report in spite of announcing plans to explore options for its Ortho Clinical Diagnostics unit, including a potential sale or spin-off... Microsoft (MSFT) is in talks to invest between $1B-$3B as part of a leveraged buyout of Dell (DELL), according to CNBC's David Faber. Dell spiked higher following the news, finishing up 28c, or 2.18%, at $13.12, while Microsoft lost 8c, or 0.29%, to $27.17... MAJOR MOVERS: Among the notable gainers was SeaCube (BOX), up $2.84, or 13.99%, to $23.14 after agreeing to be acquired by Ontario Teachers' Pension for $23 per share. Also higher were shares of Research In Motion (RIMM), which rose $2.06, or 13.01%, to $17.90 after its CEO reportedly said it may license the BB10 operating system and shares were upgraded to Outperform at Scotia Capital with a $23 price target. Among the noteworthy losers was Arena Pharmaceuticals (ARNA), which lost 95c, or 9.72%, to $8.82 after the European Medicines Agency asked it to address issues with its anti-obesity drug. Also lower were shares of II-VI (IIVI), down $1.87, or 9.51%, to $17.80 after the company's Q2 report fell short of expectations and its FY13 guidance came in below Street estimates... INDICES: The Dow was up 62.43, or 0.46%, to 13,712.13; the Nasdaq was up 8.47, or 0.27%, to 3,143.18; and the S&P 500 was up 6.53, or 0.44%, to 1,492.51.
News For TRV;JNJ;DD;VZ;DELL;MSFT;BOX;RIMM;ARNA;IIVI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 13, 2014
16:04 EDTMSFTSkullcandy announces two ASTRO headsets compatible with Xbox One
Subscribe for More Information
15:24 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
14:24 EDTJNJJohnson & Johnson October volatility increases into Q3 and outlook
Subscribe for More Information
14:15 EDTJNJEarnings Preview: Johnson & Johnson looks to new drugs to boost Q3 sales
Subscribe for More Information
14:08 EDTJNJJohnson & Johnson technical notes before earnings
Subscribe for More Information
13:10 EDTMSFTGoogle's Schmidt says Amazon is company's biggest search rival, FT reports
Eric Schmidt, the executive chairman of Google (GOOG), says Amazon (AMZN) is his company's biggest rival in search, not Bing (MSFT) or Yahoo (YHOO), the Financial Times reports. Schmidt also argued in Berlin that Google should not be regulated "as if it were the gatekeeper of the internet," given the influence of Amazon and Facebook (FB). Reference Link
09:09 EDTMSFTMicrosoft Q1 results likely to beat expectations, says Bernstein
Bernstein believes that Microsoft's cloud business continues to grow, and it expects adoption of the company's cloud products to accelerate this quarter. The firm reiterates a $56 price target and Outperform rating on the shares.
08:40 EDTJNJAlios BioPharma reports positive results for AL-8176 in Phase 2 study
Alios BioPharma presented results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176 this past weekend at the IDWeek 2014 Conference in Philadelphia, PA. The study was conducted in healthy adult volunteers who were infected intranasally with respiratory syncytial virus, or RSV. AL-8176 achieved its primary and secondary endpoints of reduction in viral load and improvement in symptom scores as compared to placebo. AL-8176 was well tolerated with no discontinuations of study drug and no clinically significant laboratory abnormalities. In successfully infected subjects, a rapid and marked reduction in RSV viral load was observed following treatment in all three AL-8176 treated dose groups as compared to placebo. In contrast, successfully infected placebo subjects exhibited a logarithmic increase in RSV RNA with a peak viral load at Day 3.5 following start of dosing with placebo. The mean time to non-detectability of RSV RNA was 1.3-2.3 days for the AL-8176 treatment groups compared to 7.2 days in the placebo group. At discharge, all subjects treated with AL-8176 were RSV RNA undetectable and remained RSV RNA undetectable upon follow-up on Days 16 and 28. The viral load reduction in infected subjects across all AL-8176 dosing regimens was associated with concomitant improvements in RSV symptom scores and reductions in mucus weight. On September 30, Johnson & Johnson announced a definitive agreement to acquire Alios.
08:05 EDTJNJBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:25 EDTJNJEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
07:15 EDTMSFT, JNJNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTJNJBioFlorida to hold a conference
Subscribe for More Information
October 10, 2014
12:05 EDTDDUSDA raises U.S. corn production estimate to 14.475B
Subscribe for More Information
11:38 EDTARNAArena, Eisai announce publication of BELVIQ Phase 3 trial
Subscribe for More Information
10:01 EDTJNJ, DDOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:19 EDTJNJMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
08:15 EDTJNJJohnson & Johnson reports additional data from ATTAIN study
Subscribe for More Information
07:07 EDTJNJJohnson & Johnson upgraded to Neutral from Underperform at Credit Suisse
Subscribe for More Information
06:27 EDTJNJJohnson & Johnson upgraded to Neutral from Underperform at Credit Suisse
05:43 EDTDDDuPont upgraded to Buy from Hold at Jefferies
Jefferies upgraded DuPont to Buy citing the pullback in shares and its belief the company's capital return program should sustain low-teens earnings growth. The firm raised its price target for shares to $84 from $72.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use